Posters and Publications
Poster Presentation – The Novel RASP Modulator Reproxalap Rapidly Improves Signs and Symptoms of Dry Eye Disease: The TRANQUILITY Run In Cohort
April 2022
Reproxalap Activity and Estimation of Clinically Relevant Thresholds for Ocular Itching and Redness in a Randomized Allergic Conjunctivitis Field Trial
Ophthalmology and Therapy (May 2022)
Bill Cavanagh, Paul J. Gomes, Christopher E. Starr, Kelly K. Nichols, Todd C. Brady
Reproxalap Improves Signs and Symptoms of Allergic Conjunctivitis in an Allergen Chamber: A Real-World Model of Allergen Exposure
CLINICAL OPHTHALMOLOGY (January 2022)
David Clark, Paul Karpecki, Anne Marie Salapatek, John D Sheppard, Todd C Brady
A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease
CLINICAL OPHTHALMOLOGY (September 2021)
David McMullin, David Clark, Bill Cavanagh, Paul Karpecki, Todd C Brady
A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (May 2021)
David Clark, John Sheppard, and Todd C. Brady
Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial
American Journal of Ophthalmology (May 2021)
David Clark, Bill Cavanagh, Alan L. Shields, Paul Karpecki, John Sheppard, Todd C. Brady
Early Onset and Broad Activity of Reproxalap in a Randomized, Double-Masked, Vehicle-Controlled Phase 2b Trial in Dry Eye Disease
American Journal of Ophthalmology, Volume 226, 22 – 31 (January 2021)
DAVID CLARK, JOSEPH TAUBER, JOHN SHEPPARD, AND TODD C. BRADY
Randomized Phase 2 Trial of Reproxalap, a Novel Reactive Aldehyde Species Inhibitor, in Patients with Noninfectious Anterior Uveitis: Model for Corticosteroid Replacement
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS (December 2020)
Kenneth J. Mandell, David Clark, David S. Chu, C. Stephen Foster, John Sheppard, and Todd C. Brady